Innate Pharma prices private placement of new shares at EUR 1.7 eachPUBT·Aug 19 at 03:03 PMIPHA-2.25%
Bpifrance Participations, Innate Pharma board director, purchases EUR 3 million of Innate Pharma sharesPUBT·Aug 14 at 11:33 AMIPHA-2.25%
IPH: Three late-stage oncology assets drive value, with major partnerships and pivotal data due in H2 2026Quartr·Aug 14 at 09:45 AMIPHA-2.25%AZN-0.35%
IPH: €30 million share offering priced, extending cash runway and funding clinical pipelineQuartr·Aug 14 at 07:05 AMIPHA-2.25%
Innate Pharma Announces Conference Call and Webcast | IPHA Stock NewsStockTitan·Aug 13 at 08:30 PMIPHA-2.25%
BTIG Research Issues Positive Forecast for Innate Pharma (NASDAQ:IPHA) Stock PriceMarket Beat·Aug 12 at 07:06 AMIPHA-2.25%
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Given Average Rating of "Moderate Buy" by AnalystsMarket Beat·Aug 11 at 07:14 AMIPHA-2.25%
Buy Rating Reiterated on Sobi as Diversified Pipeline and Lacutamab Partnership Support Upside; 12‑Month SEK575 Price Target UnchangedTip Ranks·Aug 10 at 10:35 AMIPHA-2.25%
Innate Pharma shares are trading higher after the company announced it has entered into a strategic partnership with Swedish Orphan Biovitrum AB to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma.benzinga_article·Aug 10 at 09:40 AMIPHA-2.25%
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapybenzinga_article·Aug 10 at 09:03 AMIPHA-2.25%
